182 related articles for article (PubMed ID: 31648327)
1. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma.
Stelling A; Hashwah H; Bertram K; Manz MG; Tzankov A; Müller A
Blood; 2018 May; 131(20):2235-2246. PubMed ID: 29615404
[TBL] [Abstract][Full Text] [Related]
3. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
[TBL] [Abstract][Full Text] [Related]
4. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.
Muppidi JR; Schmitz R; Green JA; Xiao W; Larsen AB; Braun SE; An J; Xu Y; Rosenwald A; Ott G; Gascoyne RD; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Vaidehi N; Staudt LM; Cyster JG
Nature; 2014 Dec; 516(7530):254-8. PubMed ID: 25274307
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
[TBL] [Abstract][Full Text] [Related]
6. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
7. β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway.
Hu T; Gao Y
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32010942
[TBL] [Abstract][Full Text] [Related]
8. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.
Xu PP; Sun YF; Fang Y; Song Q; Yan ZX; Chen Y; Jiang XF; Fei XC; Zhao Y; Leboeuf C; Li B; Wang CF; Janin A; Wang L; Zhao WL
Sci Rep; 2017 Aug; 7(1):7433. PubMed ID: 28785100
[TBL] [Abstract][Full Text] [Related]
9. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
[TBL] [Abstract][Full Text] [Related]
10. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
[TBL] [Abstract][Full Text] [Related]
11. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
[TBL] [Abstract][Full Text] [Related]
12. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma.
Schmid CA; Robinson MD; Scheifinger NA; Müller S; Cogliatti S; Tzankov A; Müller A
J Exp Med; 2015 May; 212(5):775-92. PubMed ID: 25847947
[TBL] [Abstract][Full Text] [Related]
13. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
[TBL] [Abstract][Full Text] [Related]
14. Bufalin inhibits human diffuse large B-cell lymphoma tumorigenesis by inducing cell death through the Ca2+/NFATC1/cMYC pathway.
Song J; Zou D; Zhao X; Chen Y; Lv F; Wang S; Sui D; Han Q; Yang C; Wang X; Liu B; Deng M; Zhang Y
Carcinogenesis; 2021 Feb; 42(2):303-314. PubMed ID: 33124657
[TBL] [Abstract][Full Text] [Related]
15. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
[TBL] [Abstract][Full Text] [Related]
16. S1PR2 deficiency in DLBCL: a FOXy connection.
Baldari CT
Blood; 2016 Mar; 127(11):1380-1. PubMed ID: 26989186
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
[TBL] [Abstract][Full Text] [Related]
18. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
